ZA201103723B - Human antibodies against human tissue factor - Google Patents

Human antibodies against human tissue factor

Info

Publication number
ZA201103723B
ZA201103723B ZA2011/03723A ZA201103723A ZA201103723B ZA 201103723 B ZA201103723 B ZA 201103723B ZA 2011/03723 A ZA2011/03723 A ZA 2011/03723A ZA 201103723 A ZA201103723 A ZA 201103723A ZA 201103723 B ZA201103723 B ZA 201103723B
Authority
ZA
South Africa
Prior art keywords
antibodies against
tissue factor
human
human antibodies
human tissue
Prior art date
Application number
ZA2011/03723A
Other languages
English (en)
Inventor
Sandra Verploegen
David P E Satijn
Rene M A Hoet
Paul Parren
De Winkel Jan Van
Vibele Miller Breinholt
Eva Ehrnrooth
Ole Baadsgaard
Tom Vink
Willem Karel Bleeker
Mischa Houtkamp
Maroeska Oudshoorn
Jong Rob N De
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of ZA201103723B publication Critical patent/ZA201103723B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2011/03723A 2008-12-09 2011-05-20 Human antibodies against human tissue factor ZA201103723B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20133508P 2008-12-09 2008-12-09
DKPA200801744 2008-12-09
PCT/EP2009/066755 WO2010066803A2 (en) 2008-12-09 2009-12-09 Human antibodies aganist tissue factor.

Publications (1)

Publication Number Publication Date
ZA201103723B true ZA201103723B (en) 2012-09-26

Family

ID=59050110

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/03723A ZA201103723B (en) 2008-12-09 2011-05-20 Human antibodies against human tissue factor

Country Status (21)

Country Link
US (7) US9150658B2 (OSRAM)
EP (3) EP4279140A3 (OSRAM)
JP (6) JP5860285B2 (OSRAM)
KR (2) KR101998492B1 (OSRAM)
CN (3) CN119331096A (OSRAM)
AU (1) AU2009324412B2 (OSRAM)
BR (1) BRPI0922350B8 (OSRAM)
CA (2) CA2746101C (OSRAM)
DK (1) DK2376537T3 (OSRAM)
EA (1) EA201100923A1 (OSRAM)
ES (1) ES2604635T3 (OSRAM)
IL (1) IL212856A (OSRAM)
MX (2) MX338754B (OSRAM)
NZ (1) NZ786274A (OSRAM)
PL (1) PL2376537T3 (OSRAM)
PT (1) PT2376537T (OSRAM)
SG (1) SG10201500140VA (OSRAM)
SI (1) SI2376537T1 (OSRAM)
UA (1) UA109633C2 (OSRAM)
WO (1) WO2010066803A2 (OSRAM)
ZA (1) ZA201103723B (OSRAM)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
EP3153524B1 (en) * 2008-12-03 2025-04-23 Genmab A/S Antibody variants having modifications in the constant region
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
NZ604003A (en) 2010-05-27 2015-04-24 Genmab As Monoclonal antibodies against her2
EP3281956A3 (en) * 2010-06-15 2018-04-18 Genmab A/S Human antibody drug conjugates against tissue factor
MX349057B (es) * 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
US8722044B2 (en) * 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
WO2012143523A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US9555109B2 (en) * 2012-01-20 2017-01-31 University Of Cincinnati Method of inhibiting cell proliferation induced by alternatively spliced tissue factor by administering a monoclonal antibody
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
ES2984345T3 (es) 2013-01-10 2024-10-29 Genmab Bv Variantes de la región FC de IGG1 humana y usos de las mismas
JP2017502983A (ja) * 2013-10-02 2017-01-26 スリ テクノロジーズ エルティーディー． 不均一な腫瘍を処置するための患者特異的免疫療法
ES2983564T3 (es) 2013-11-21 2024-10-23 Genmab As Formulación liofilizada de conjugado de anticuerpos y fármaco
WO2016077720A1 (en) * 2014-11-14 2016-05-19 Protein One, Llc Binding agents and uses thereof
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6858128B2 (ja) 2015-02-18 2021-04-14 エンリヴェックス セラピューティクス リミテッド 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN113106053A (zh) 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
WO2017028823A1 (zh) * 2015-08-20 2017-02-23 复旦大学 靶向于组织因子的抗体、其制备方法和用途
HUE055109T2 (hu) 2015-09-11 2021-11-29 Genmab As Adagolási rendek TF elleni antitest és gyógyszer konjugátumaihoz
EP3416661A4 (en) 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER
US10676537B2 (en) 2016-08-22 2020-06-09 Fudan University Antibody targeted to tissue factor, preparation method therefor, and use thereof
CN106938051B (zh) 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
WO2018085400A1 (en) 2016-11-02 2018-05-11 Vanderbilt University Human zika virus antibodies and methods of use therefor
BR112019011277A2 (pt) 2016-12-02 2019-10-22 University Of Southern California polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
TW201922796A (zh) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
JP2021501776A (ja) * 2017-11-02 2021-01-21 ゲンマブ エー／エス 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用
WO2019136309A1 (en) 2018-01-04 2019-07-11 Iconic Therapeutics, Inc. Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
BR112020018092A2 (pt) * 2018-03-07 2020-12-22 Genmab A/S Método para tratar câncer em um sujeito, estojo, uso de um conjugado anticorpo-fármaco que se liga ao fator tecidual, e, conjugado anticorpo-fármaco.
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CA3096705A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
MX2021001058A (es) * 2018-08-16 2021-04-12 Genmab As Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de un cancer.
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN109840471B (zh) * 2018-12-14 2023-04-14 天津大学 一种基于改进Unet网络模型的可行道路分割方法
WO2020132684A2 (en) * 2018-12-21 2020-06-25 Board Of Regents, The University Of Texas System Phosphorylated dicer antibody and methods of use thereof
EP3917564A4 (en) * 2019-02-01 2022-12-21 NovaRock Biotherapeutics, Ltd. ANTI-CLAUDINE 18 ANTIBODIES AND THEIR METHODS OF USE
US12264197B2 (en) 2019-03-11 2025-04-01 Janssen Biotech, Inc. Anti-Vβ17/anti-CD123 bispecific antibodies
CN113692415B (zh) 2019-04-17 2025-01-07 诺和诺德股份有限公司 双特异性抗体
WO2021090272A1 (en) 2019-11-07 2021-05-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
MX2022012621A (es) 2020-04-10 2023-01-18 Seagen Inc Enlazadores de variantes de carga.
AU2021299947A1 (en) 2020-06-29 2022-12-22 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
AU2021304359A1 (en) * 2020-07-10 2023-03-02 Iconic Therapeutics Llc Inflammatory disease treatment using anti-tissue factor antibodies
BR112023002488A2 (pt) 2020-08-10 2023-05-02 Janssen Biotech Inc Materiais e métodos para produzir linfócitos biomodificados contra vírus específicos
US11965024B2 (en) 2020-09-11 2024-04-23 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
WO2022056197A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
KR20230171980A (ko) 2021-04-20 2023-12-21 씨젠 인크. 항체 의존성 세포 독성의 조절
AU2022283467A1 (en) 2021-05-28 2023-12-07 Seagen Inc. Anthracycline antibody conjugates
WO2023137399A2 (en) * 2022-01-12 2023-07-20 Iconic Therapeutics Llc Inflammatory disease treatment using anti-tissue factor antibodies
KR20250004952A (ko) 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체
US20250302982A1 (en) 2022-05-06 2025-10-02 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
KR20250090287A (ko) 2022-10-19 2025-06-19 멀티튜드 테라퓨틱스 인코퍼레이티드 항체, 항체-약물 접합체, 이의 제조 및 용도
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024222868A1 (zh) 2023-04-28 2024-10-31 江苏恒瑞医药股份有限公司 抗tf抗体和抗tf抗体-药物偶联物及其医药用途
WO2025081117A2 (en) * 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
TW202535940A (zh) 2023-10-24 2025-09-16 美商思進公司 化學治療化合物及使用方法
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025240305A1 (en) * 2024-05-13 2025-11-20 Manifold Biotechnologies, Inc. Methods and compositions for targeted delivery of therapeutics

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5437864A (en) 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
JP2749167B2 (ja) 1988-06-21 1998-05-13 ジェネンテク，インコーポレイテッド 心筋梗塞の処置のための方法および治療用組成物
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP1484412A3 (en) 1989-12-22 2007-10-17 Laboratoires Serono SA Eukaryotic host cell line in which an endogenous gene has been activated, and uses thereof
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
JP3149960B2 (ja) 1991-01-24 2001-03-26 財団法人化学及血清療法研究所 ヒト組織因子を定量する方法
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
JPH05244988A (ja) 1992-03-04 1993-09-24 Green Cross Corp:The 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU5093593A (en) 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5879677A (en) 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
EP0804070B1 (en) 1993-03-09 2000-05-24 Genzyme Corporation Process of isolation of proteins from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5879687A (en) 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
ATE198712T1 (de) 1994-07-11 2001-02-15 Univ Texas Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
DE69632465T2 (de) 1995-06-07 2005-06-23 Ortho-Mcneil Pharmaceutical, Inc. Cdr-transplantierte antikörper gegen "tissue factor" und verfahren zur deren verwendung
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
JPH09302000A (ja) 1996-05-16 1997-11-25 Chemo Sero Therapeut Res Inst 抗組織因子モノクローナル抗体及び当該モノクローナル抗体を用いた組織因子凝固活性の測定法
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US20040229282A1 (en) 1997-03-10 2004-11-18 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
US6235523B1 (en) 1998-09-04 2001-05-22 Connaught Laboratories Limited Vectors for DNA immunization against cervical cancer
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
PT1150918E (pt) 1999-02-03 2005-01-31 Biosante Pharmaceuticals Inc Metodo de fabrico de particulas terapeuticas de fosfato de calcio
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
AU6375000A (en) 1999-07-29 2001-02-19 Medarex, Inc. Human monoclonal antibodies to her2/neu
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
JP2001213804A (ja) 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd 抗組織因子抗体の複合体
JP2003527861A (ja) 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
WO2002042468A2 (en) 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US20040180051A1 (en) 2001-03-26 2004-09-16 Koji Suzuki Blood rheology improving agents
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
NZ531211A (en) 2001-08-23 2007-04-27 Genmad As Human antibodies specific for interleukin 15 (IL-15)
WO2003020111A2 (en) 2001-08-30 2003-03-13 Mount Sinai School Of Medicine Of New York University Alternatively spliced circulating tissue factor
KR20040045478A (ko) * 2001-10-02 2004-06-01 노보 노르디스크 에이/에스 인간 조직인자 항체
US20050169927A1 (en) * 2001-10-02 2005-08-04 Novo Nordisk A/S Human tissue factor antibodies
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003037361A2 (en) 2001-11-02 2003-05-08 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US20050255111A1 (en) 2002-02-22 2005-11-17 Olle Korsgren Use of an inhibitor or antagonist against tissue factor
RS102404A (sr) 2002-05-01 2006-12-15 Schering Aktiengesellschaft Nova antitela koja ciljaju tkivni faktor kao antikoagulanti
WO2004007557A2 (en) 2002-07-12 2004-01-22 Novo Nordisk A/S Tf antagonist
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
AU2003277832A1 (en) * 2002-10-31 2004-05-25 Novo Nordisk A/S Humanized tissue factor antibodies
WO2004041302A1 (en) 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
WO2004041296A2 (en) 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
WO2004064870A2 (en) 2003-01-22 2004-08-05 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
US20060034846A1 (en) 2003-04-14 2006-02-16 Mirella Ezban Use of TF antagonists
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
CA2527621A1 (en) 2003-05-30 2004-12-23 Centocor, Inc. Method of inhibiting tumor growth with anti-tissue factor antibodies
AU2004251161A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
CA2530980A1 (en) 2003-06-19 2005-01-20 Tanox, Inc. Tissue factor-specific antibodies for preventing or treating acute lung injury or acute respiratory distress syndrome
WO2005025623A2 (en) 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
JP2007504167A (ja) 2003-08-29 2007-03-01 セントカー・インコーポレーテツド 抗組織因子抗体を用いる移植片の生存を向上する方法
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
DK1691837T3 (da) 2003-12-10 2012-10-01 Medarex Inc IP-10-antistoffer og anvendelse heraf
EP1744734A2 (en) 2004-02-20 2007-01-24 Novo Nordisk A/S Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
EP1945264A2 (en) 2005-10-21 2008-07-23 Genentech, Inc. Treatment for antiphospholipid-syndrome-related pregnancy complications
AU2006311661B2 (en) * 2005-11-07 2011-05-26 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
WO2007076091A2 (en) 2005-12-22 2007-07-05 Genentech, Inc. Treatment of viral infections using a tissue factor inhibitor
CA2685698A1 (en) 2007-04-30 2008-11-13 Centocor Ortho Biotech Inc. Anti-tissue factor antibodies and compositions with enhanced effector function
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP3281956A3 (en) 2010-06-15 2018-04-18 Genmab A/S Human antibody drug conjugates against tissue factor

Also Published As

Publication number Publication date
JP2016138089A (ja) 2016-08-04
CN119331096A (zh) 2025-01-21
NZ786274A (en) 2023-09-29
MX338754B (es) 2016-04-29
WO2010066803A3 (en) 2010-08-19
CN102317319B (zh) 2016-06-29
MX2011005669A (es) 2011-06-17
PT2376537T (pt) 2016-12-26
US20250340669A1 (en) 2025-11-06
MX355181B (es) 2018-04-09
US9714297B2 (en) 2017-07-25
JP2018038418A (ja) 2018-03-15
EA201100923A1 (ru) 2011-12-30
CN106632678A (zh) 2017-05-10
KR20170056025A (ko) 2017-05-22
UA109633C2 (uk) 2015-09-25
JP2012511314A (ja) 2012-05-24
JP6592491B2 (ja) 2019-10-16
CA2746101A1 (en) 2010-06-17
KR20110104944A (ko) 2011-09-23
US20180044431A1 (en) 2018-02-15
BRPI0922350B1 (pt) 2021-01-12
PL2376537T3 (pl) 2017-06-30
CA3017575A1 (en) 2010-06-17
IL212856A0 (en) 2011-07-31
EP4279140A3 (en) 2024-01-31
EP2376537A2 (en) 2011-10-19
US20190169311A1 (en) 2019-06-06
BRPI0922350B8 (pt) 2021-05-25
AU2009324412A1 (en) 2011-06-30
US20160053020A1 (en) 2016-02-25
SI2376537T1 (sl) 2017-02-28
JP2022078018A (ja) 2022-05-24
JP6236056B2 (ja) 2017-11-22
IL212856A (en) 2016-09-29
KR101736447B1 (ko) 2017-05-16
KR101998492B1 (ko) 2019-07-09
BRPI0922350A2 (pt) 2016-01-12
JP7069095B2 (ja) 2022-05-17
WO2010066803A2 (en) 2010-06-17
US20230416403A1 (en) 2023-12-28
EP3159358B1 (en) 2023-10-11
JP2024001285A (ja) 2024-01-09
US20110300156A1 (en) 2011-12-08
CN102317319A (zh) 2012-01-11
CA2746101C (en) 2018-10-30
JP2020022461A (ja) 2020-02-13
EP2376537B1 (en) 2016-09-28
US9150658B2 (en) 2015-10-06
CN106632678B (zh) 2022-05-31
ES2604635T3 (es) 2017-03-08
EP3159358A1 (en) 2017-04-26
SG10201500140VA (en) 2015-03-30
US20210171657A1 (en) 2021-06-10
DK2376537T3 (en) 2017-01-23
AU2009324412B2 (en) 2016-04-21
JP5860285B2 (ja) 2016-02-16
EP4279140A2 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
IL212856A0 (en) Human antibodies against human tissue factor
HUS2500017I1 (hu) Szöveti faktor bioszintézis út elleni ellenanyagok
PL2949666T3 (pl) Ludzkie przeciwciała przeciwko alfa-synukleinie
ZA201307297B (en) Antibodies against human angiopoietin 2
IL208979A0 (en) Humanized antibodies against human interferon-alpha
GB0807018D0 (en) Antibodies and treatment
IL212795A0 (en) Fully human antibodies against n-cadherin
GB0815788D0 (en) Therapeutic antibodies
IL216440A0 (en) Antibodies against human ccn1 and uses thereof
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
GB0812940D0 (en) Medical implant
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
SG10202006468XA (en) Human antibodies against human tissue factor
HK1163135A (en) Human antibodies against human tissue factor
PH32008000854S1 (en) Tissue
GB0805534D0 (en) Medical Aid
GB0800146D0 (en) Medical aid
GB0809735D0 (en) Medical implant
GB0809820D0 (en) Modified tissues
IL212647A0 (en) Tissue adhesive
GB0819010D0 (en) Medical uses
GB0809339D0 (en) Medical uses
GB0809333D0 (en) Medical uses
TWM347115U (en) Tableware for healthy living